[Updated 4:15pm ET with pharma industry trade group comment, see below.] When the Trump administration announced its blueprint for lowering prescription drug prices in May, many observers said it was too soft on the biopharma industry and didn’t contain concrete initiatives that could truly cut costs.
But with the U.S. midterm elections fast approaching and the high cost of drugs and healthcare remaining a key issue with voters of both political parties, President Trump today announced some more aggressive moves, starting with a plan to lower prices for some drugs covered by Medicare.
After much rhetoric from Trump… Read more »
UNDERWRITERS AND PARTNERS